公开(公告)号：US20170342027A1

公开(公告)日：2017-11-30

申请号：US15325349

申请日：2016-02-15

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byoung Young WOO ,  Ki-Wha LEE ,  Kwang-Hyun SHIN ,  Miyoung PARK ,  Kyoungmi JUNG ,  Joonho CHOI ,  Gyeyoung CHOI ,  Wonkyung CHO ,  Young-Ho PARK

IPC: C07C303/42 ,  C07C63/06 ,  C07B57/00 ,  C07C311/08 ,  C07C303/36

CPC classification number: C07C303/42 ,  C07B57/00 ,  C07B2200/07 ,  C07C63/06 ,  C07C303/36 ,  C07C303/44 ,  C07C311/08 ,  C07D213/56

Abstract: The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O′-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O′-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

公开(公告)号：US20200031766A1

公开(公告)日：2020-01-30

申请号：US16337729

申请日：2017-09-26

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byoung Young WOO ,  Ki-Wha LEE ,  Jihae LEE ,  Chang Soon CHOI ,  Miyoung PARK ,  Young-Ho PARK ,  Sarva JAYAPRAKASH ,  Sridhar REGATI ,  Mamidi SRINIVAS ,  Krushnakant PATEL ,  M. RAMAMOHAN

IPC: C07C311/08 ,  C07C303/44 ,  B01D9/00

Abstract: Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the re-crystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.

公开(公告)号：US20140011881A1

公开(公告)日：2014-01-09

申请号：US14022789

申请日：2013-09-10

Applicant: Amorepacific Corporation

Inventor： Song Seok SHIN ,  Jin Kwan KIM ,  Sun-Young KIM ,  Ki-Wha LEE ,  Byoung young WOO ,  Joo-Hyun MOH ,  Yeon Su JEONG ,  Kyung Min LIM ,  Jin Kyu CHOI ,  Hyun-Ju KOH ,  Young-Ho PARK

IPC: C07C311/08

CPC classification number: C07C311/08 ,  C07C2601/14 ,  C07D295/145

Abstract: This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same.The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.

Abstract translation: 本公开涉及新化合物，其异构体或其药学上可接受的盐作为香草素受体（Vanilloid Receptor 1; VR1; TRPV1）拮抗剂; 和含有该组合物的药物组合物。 本公开提供了用于预防或治疗诸如疼痛，偏头痛，关节痛，神经痛，神经病，神经损伤，皮肤病，尿膀胱过敏症，肠易激综合征，粪便紧急性，呼吸障碍，皮肤刺激， 眼或粘膜，胃十二指肠溃疡，炎性疾病，耳病，心脏病等。

公开(公告)号：US20200215040A1

公开(公告)日：2020-07-09

申请号：US16638038

申请日：2018-08-10

Applicant: AMOREPACIFIC CORPORATION

Inventor： Joon Ho CHOI ,  Won Kyung CHO ,  Kwang-Hyun SHIN ,  Byoung Young WOO ,  Ki-Wha LEE ,  Min-Soo KIM ,  Jong Hwa ROH ,  Mi Young PARK ,  Young-Ho PARK ,  Eun Sil PARK ,  Jae Hong PARK

IPC: A61K31/44 ,  A61K47/38 ,  A61K9/00

Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.